PM — Philip Morris International Inc.

Summary of Philip Morris International Inc. Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Total Net Revenues: Exceeded $40 billion in 2025, with 41.5% ($17 billion) from smoke-free products.
• Adjusted Diluted EPS: Grew 15% to $7.54, reflecting a currency-neutral growth of 14%.
• Organic Net Revenue Growth: Increased by 6.5%, with a stronger performance of 7.9% excluding technical impacts from Indonesia.
• Operating Income: Adjusted operating income rose 11.8% to $16.4 billion, with an organic operating income growth of 10.6%.
• Operating Cash Flow: Matched the record of $12.2 billion from 2024.
• Smoke-Free Product Volumes: Grew by 12.8%, with IQOS shipments increasing by 11%.

2. Strategic Updates and Business Highlights

• PMI continues to lead the shift towards smoke-free alternatives, with a strong multi-category strategy.
• The company expanded its smoke-free product presence to 106 markets, with significant growth in IQOS and nicotine pouches (ZYN).
• ZYN achieved a 37% growth in the U.S. despite supply constraints, and its international presence expanded to 56 markets.
• The e-vapor brand, VIVE, is now the fastest-growing international vape brand.
• PMI's smoke-free gross profit contribution doubled over five years, reaching 43% of total PMI gross profit.

3. Forward Guidance and Outlook

• For 2026, PMI anticipates organic net revenue growth of 5-7% and adjusted diluted EPS growth of 7.5-9.5%.
• The company expects continued strong growth in smoke-free products, with high single-digit growth in shipments and adjusted IMS volumes.
• Combustible volumes are projected to decline by around 3%, with challenges in markets like India and Mexico due to recent excise tax increases.
• PMI aims to achieve a leverage ratio close to 2x by 2026, supporting shareholder returns through dividends.

4. Bad News, Challenges, or Points of Concern

• Excise Tax Headwinds: Upcoming excise tax increases in Japan are expected to impact growth and margins in 2026.
• Competitive Pressures: Increased competition in Japan and the U.S. could affect market share and growth rates.
• Cigarette Volume Decline: A slight decline in cigarette volumes (1.5% in 2025) is anticipated to continue, with a forecasted decline of around 3% for 2026.
• Regulatory Risks: Potential excise tax increases on nicotine pouches in New York and other states could hinder growth and profitability.

5. Notable Q&A Insights

• Management emphasized that the growth in smoke-free products is expected to continue despite regulatory challenges and competitive pressures.
• There was a discussion on the anticipated impact of the FDA's decisions regarding ZYN Ultra and IQOS ILUMA, with management expressing optimism about future approvals.
• The company plans to balance promotional activities for ZYN while awaiting FDA decisions, indicating a strategic pause in aggressive promotions.
• Management highlighted the importance of maintaining brand equity and product innovation to drive future growth, particularly in the U.S. market.

Overall, PMI reported strong financial results for 2025, driven by its smoke-free product strategy, while also acknowledging regulatory and competitive challenges ahead. The company remains optimistic about its growth trajectory and shareholder returns in the coming years.